Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for that Whale! Just snapped up 1 Million Shares! Thanks!
Well if it does go down to 0.0045 I just snap up a few Million Shares!
100% CORRECT!!!
Yes, between them they likely hold a large percentage of the Float, sever hundred million shares. Their goal is to become a Billionaire over night, but they don't want anyone else to!
100% CORRECT!! He ain't foolin NO ONE!
Well said, and not only that one of the Cotropia brothers is an Attorney and it's very unlikely they would of signed a binding letter of intent if they didn't have all their ducks in order and very aware they need to come current with SEC filings. This matter is a "no brainer" for professionals of this caliber on both sides of the track.
Well said!
My forward looking guesstimate on ENZC PPS is this:
(conservative estimates only)
1). News Merger official: $0.25 - $1.0
PLUS:
2). News Funding official: $1.5 - $4.50
PLUS:
3). News BigPharma Partner named for commercialization: $5.00 - $6.00
PLUS:
4). Patient Clinical Trials underway Phase I-IV: $7 - $10.
PLUS:
5). Commercialization (pre earnings): $12 - $20
Please keep in mind CytoDyn's 52 week run was $0.52 to $10 not long ago under similar circumstances, has an inferior Monoclonal Ab Patent as previously discussed here, is currently trading in $3 range, and still has not reached market., no sales, no earnings!
All feedback welcome, and again, this is only speculation.
Be well and prosper ...
HIGH VOLUME SELLING ALL DAY!
14:1
There were 14X the number of Sellers than Buyers, and the great benefit in that is basement bargain shares to snap up in HUGE VOLUME with a drop in the pps!!!
Adding to my position on these major dips...no problem...not worried in the least!
Great way to accumulate several MILLION shares the way I see it!
Just think, if you're holding just 3 Million Shares at this penny range, when it hits $1 not long from now you'll be an instant Multi-Millionaire, then onward to $5 then $10!
Be well and prosper .....
I agree! But with profit taking it could likely pull back to .015-.016
Be well and prosper ...
Very elegantly put! 100% CORRECT across the board!
Much is converging here...right place...right time...right players...Disruptive Technology....the only curative hope for HIV in sight standing before humanity...readily available massive funding from many sources...the time to make it happen is NOW!!!
Enzolytics-BioClonetics....a global BigPharma Superstar in the making unlike anything the world has ever seen!
Time for liftoff!
Be well and prosper ....
EXCELLENT POST...THANKS! I didn't see this before but now it's on my radar for thorough review!
Be well and prosper ....
As promised here's The U.S. Patent Office Database Search for Dr. Fauci vs. Dr. Cotropia's Biomedical Research Patent History
Dr. Fauci
No. of Patents: 1,848
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&Query=fauci
Dr. Cotropia
No. of Patents: 242
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&Query=Cotropia
Based on this information proving Dr. Cotropia's world class Bio-Medical Science Research background that fundamentally is "on par" with Dr. Fauci, combined with Cotropia's superior Clone-3 Antibody Patent that clearly represents "Disruption Technology" for potential AIDS/HIV curative treatment as a Monotherapy approach for most HIV strains, and possibly Covid-19, the above is all I needed to see to make the decision to invest in Enzolytics-BioClonetics. For me it was a "no brainer", it didn't take a lot of thought because I know who these guys are!
The clinical implications of this is extraordinarily profound and the Patent Cotropia holds on Clone-3, in and of itself, and all by itself, independent of bringing it to market, is worth $$Billions$$ far beyond any AIDS/HIV drug therapies that have been commercialized for clinical application thus far.
There's nothing like this that presently exists in the marketplace.
Let me be very clear about something, both Fauci and Cotropia are world class leaders in infectious disease investigational research and treatment.
Therefore, it was an easy decision for me to invest in Enzolytics-Bioclonetics based on my own Bio-Medical Science research background in University based Academic Medicine & BigPharma Clinical Research patient trials.
Be well and prosper .....
Thank you for your feed back! I performed a lot of DD to put all that together and actually stumbled upon it by surprise and don't really recall how that happened! LOL!
One thing's for certain, what I discovered should dispel the notion of Enzolytics-BioClonetics not being legit for anyone on this message board, when in fact they're just as legit and in the exact same league doing the exact same thing as CytoDyne-Vyera, and to boot, CytoDyne's stock pps was no different a little more than year ago than Enzolytics is today! It was and still is a "Penny Stock" trading on the OTC with no product on the market as of yet, but yet they have traded in the $10 range on a 52 Week High, and have pulled back since then to the $3 range presently.
Not only this, due to my professional background in BigPharma as an M.D. Clinical Trials professional, I'm very tuned into something in this industry being legitimate or not, and the first thing I look at like ALL professionals is who is it behind the scenes that's at the helm of a company of this perceived magnitude, and I got my answer to that question very quickly because I thoroughly investigated the history of Dr. Cotropia who is probably among the most innovative scientist-clinical investigators I've seen in a long time, even on the same level as Dr. Fauci. I even looked into the Patents he has under his belt over the past 30 years which I will soon post. He has almost as many Patents as Dr. Fauci, so this speaks volumes to who he is and what's underway at BioClonetics and their partnership with Enzolytics. Both are on the same level as CytoDyne-Vyera Pharmaceuticals.
So yes, BioClonetics-Enzolytics is definitely legit and everyone on this message board needs to hear that from me because I come from the same academic and BigPharma industry they're both in.
Lastly a week ago, I would of never thought i'd be looking at Penny Stocks to invest in, and even that I don't recall how it happened.
But it didn't take me long to comprehend what I was looking at, and I initiated a small position of less than 1,100 shares, but since then have already increased to 1/2 Million Shares. In the coming weeks, I will likely increase it to 1 Million even at any ground floor pps range because something like this will probably not be seen again if ever, as most Biopharmaceutical Companies open on the Market as an IPO and come out trading on the major exchanges well into the double digit dollar range.
Thank you again for your feed back and look for my next post on Dr. Fauci vs. Dr. Cotropia's lengthy Patent history.
Be well and prosper .....
Many of you may be interest in learning about a parallel rival to Enzolytics-Bioclonetics I was discussing today with an Immunologist colleague of mine from the BigPharma Industry.
During our discussion, I mentioned that Endolytics-BioClonetics is currently in the process of merging, and that post-merger as one company, they will collaborate to bring the Clone-3 Monoclonal Ab to market for curative treatment of 95% of AIDS/HIV strains. We discussed the various immunological implications of this as an effective treatment for HIV.
When I mentioned this, he was very surprised and also not familiar with Enzolytics or BioClonetics. However he informed me that a Company by the name of CytoDyne has a proprietary patent on a laboratory engineered monoclonal antibody by the name of Leronlimab (P140) they're developing for commercialization for HIV & Covid-19 treatment that follows the basic Mechanism of Action as BioClonetic's Clone-3 Ab., i.e. it binds to the surface of cells preventing the entry of the HIV virus.
CytoDyne's antibody apparently is a "humanized" form of the naturally occurring antibody by the name of Leronlimab (P 140). However, looking into this further CytoDyne reveals that their Phase-III trials of Leonlimab (P-140) have only been effective in moderate suppression of viral load, and it has NOT been identified as being effective in all known stains of HIV Virus sub-types of which there are at least 89. So far it appears that they're treating only HIV-1, NOT HIV-2, and NOT any of the associated HIV sero-type sub-classes.
Also, this therapy requires daily combined doses of the HIV standard treatment protocol known as Anti-Retro-Viral (A.R.T.) drug therapy in tandem. Therefore, it's NOT Monotherapy like BioClonetics Clone 3 Ab; a major difference. This is also in contrast to Clonetics Clone-3 being effective in up to 95% of all known HIV primary class and sub-types.
More specifically, CytoDyn’s Leronlimab (PRO 140) monoclonal antibody, is a humanized "IgG-4 mAb" that blocks CCR5, a cellular receptor that has a role not only with HIV infection, but also in tumor metastases and immune signaling. I researched this on CytoDyne's website and discovered they have successfully completed nine Phases 1-3 clinical trials, including a successful pivotal Phase 3 trial in combination with standard anti-retroviral therapies in HIV-infected patients. Overall, there at least 64 Monoclonal Antibodies in existence that have been developed into drug therapies for treating various diseases.
Apparently what CytoDyne has with its Leronlimab (P140) is so promising based on their preliminary trials, they've been granted FDA Approval for fast-track development for treating HIV, and Emergency Development for treating Covid-19.
https://www.drugs.com/history/leronlimab.html
So CytoDyne is well on its way to commercialization of Leronlimab (P140) for treating HIV, Covid-19, and several others diseases, and like Enzolytics, they're trading on the OTC under the symbol: CYDY with a share price of $3.27 as of Friday 10/9/20 close of market.
I mention this last point because it reveals that although this company has NO products on the market and no revenues, their stock PPS is currently trading in the $3 range. Within the past 52-Weeks it had a trading range of $0.52-$10.00. My point here is they got their start NO DIFFERENT than Enzolytics-BioClonetics as an HIV drug development company listed on the OTC, and I discover that prior to the past 52 Weeks, they were trading at a low of $0.16. It's interesting to note that CytoDyne's share price rose to $0.42 upon announcement they partnered into a commercialization and license agreement with Vyera Pharmaceuticals LLC who holds the Patent on Leronlimbab (PRO 140) to commercialize it in the U.S. for HIV treatment. From there, within less than a year CytoDyne's PPS rose to as high as $10. (take a look at it's trading history).
Relative this partnership, CytoDyne will be responsible for the development and FDA approval of leronlimab (PRO-140) for HIV treatment including related indications, while Vyera will have exclusive license to market and distribute leronlimab (P140) in the U.S. Additionally, Vyera has agreed to pay upfront regulatory and sales-based milestone payments of up to $87.5 Million, as well as a royalty of 50% on net sales to CytoDyne. Furthermore, Vyera also agreed to purchase $4 Million of Cytodyne's stock.
Here's the links to:
1), CytoDyne: https://www.cytodyn.com
2). Vyera Pharmaceuticals: https://www.vyera.com
3). CytoDyne & Vyera Pharmaceuticals partnership arrangements that just took place 10-Months ago in December 2019:
https://www.globenewswire.com/news-release/2019/12/17/1961907/0/en/CytoDyn-Signs-Definitive-Agreements-with-Vyera-Pharmaceuticals-to-Commercialize-Leronlimab-in-the-U-S-for-the-Treatment-of-HIV.html
4). CytoDyne engaged in application of their Leronlimab (P-140) for treating Covid-19
https://www.cytodyn.com/newsroom/press-releases/detail/453/update---impressive-results-from-cytodyns-phase-2
https://www.sec.gov/Archives/edgar/data/1175680/000119312520004683/d855842dex105.htm
5), CytoDyne's Proproetary Leronlimab (PRO-140): https://en.wikipedia.org/wiki/PRO_140
6). CytoDyne's Stock Soars After Partnering with Vyera Pharmaceuticals:
https://www.proactiveinvestors.com/companies/news/909402/cytodyn-soars-after-partnering-with-vyera-pharmaceuticals-to-commercialize-leronlimab-in-us-to-treat-hiv-909402.html
It's probably obvious by now I'm contrasting forward looking developments with Enzolytics-BioClonetics relative to what happened between CytoDyne & Vyera Pharmaceuticals, keeping in mind that CytoDyne's stock pps rose very quickly upon news of their official partnership. I believe the same thing will happen post-merger of Enzolytics & BioClonetics, and again, when they contract out the commercialization of their Clone-3 Ab with a Major BigPharma player that has the infrastructure and resources to make it happen.
I believe they follow a similar pattern coming into the pharmaceutical marketplace. The question remains however, that upon post-merger into one company, who will they seek out as a partner developer of their Clone 3 technology to bring their product to commercialization? I believe by far they have a superior Monoclonal Antibody technology for treating HIV Virus and related infectious disease viruses including Covid-19, compared to CytoDyne-Vyera.
So CytoDyne is well on its way to commercialization of Leronlimab (P140) for treating HIV, Covid-19, and several others diseases, and like Enzolytics, they're trading on the OTC under the symbol: CYDY with a share price of $3.27 as of Friday 10/9/20 close of market.
I mention this last point because it reveals that although this company has NO products on the market and no revenues, their stock PPS is currently trading in the $3 range. Within the past 52-Weeks it had a trading range of $0.52-$10.00. My point here is they got their start NO DIFFERENT than Enzolytics-BioClonetics as an HIV drug development company listed on the OTC, and I discover that prior to the past 52 Weeks, they were trading at a low of $0.16. It's interesting to note that CytoDyne's share price rose to $0.42 upon announcement they partnered into a commercialization and license agreement with Vyera Pharmaceuticals LLC who holds the Patent on Leronlimbab (PRO 140) to commercialize it in the U.S. for HIV treatment. From there, within less than a year CytoDyne's PPS rose to as high as $10. (take a look at it's trading history).
Relative to the terms of this partnership, CytoDyn will be responsible for the development and FDA approval of leronlimab (PRO-140) for HIV treatment including related indications, while Vyera will have exclusive license to market and distribute leronlimab (P140) in the U.S.
Additionally, Vyera has agreed to pay upfront regulatory and sales-based milestone payments of up to $87.5 Million, as well as a royalty of 50% on net sales to CytoDyne. Furthermore, Vyera also agreed to purchase $4 Million of Cytodyne's stock.
Here's the links to:
1), CytoDyne: https://www.cytodyn.com
2). Vyera Pharmaceuticals: https://www.vyera.com
3). CytoDyne & Vyera Pharmaceuticals partnership arrangements that just took place 10-Months ago in December 2019:
4). CytoDyne engaged in application of their Leronlimab (P-140) for treating Covid-19
https://www.cytodyn.com/newsroom/press-releases/detail/453/update---impressive-results-from-cytodyns-phase-2
https://www.globenewswire.com/news-release/2019/12/17/1961907/0/en/CytoDyn-Signs-Definitive-Agreements-with-Vyera-Pharmaceuticals-to-Commercialize-Leronlimab-in-the-U-S-for-the-Treatment-of-HIV.html
https://www.sec.gov/Archives/edgar/data/1175680/000119312520004683/d855842dex105.htm
5), CytoDyne's Proproetary Leronlimab (PRO-140): https://en.wikipedia.org/wiki/PRO_140
6). CytoDyne's Stock Soars After Partnering with Vyera Pharmaceuticals:
https://www.proactiveinvestors.com/companies/news/909402/cytodyn-soars-after-partnering-with-vyera-pharmaceuticals-to-commercialize-leronlimab-in-us-to-treat-hiv-909402.html
It's probably obvious by now I'm contrasting forward looking developments with Enzolytics-BioClonetics relative to what happened between CytoDyne & Vyera Pharmaceuticals, keeping in mind that CytoDyne's stock pps rose very quickly upon news of their official partnership. I believe the same thing will happen post-merger of Enzolytics & BioClonetics, and again, when they contract out the commercialization of their Clone-3 Ab with a Major BigPharma player that has the infrastructure and resources to make it happen.
I believe they follow a similar pattern coming into the pharmaceutical marketplace. The question remains however, upon post-merger into one company, who will they seek out as a partner developer of their Clone 3 technology to bring their product to commercialization? I believe by far they have a superior Monoclonal Antibody technology for treating HIV Virus and related infectious disease viruses including Covid-19, compared to CytoDyne-Vyera.
I hope this review was of interest to everyone.
Be well and prosper .....
20/20 Video on BioClonetics!
Thank you for confirming.
Thank you for that, I was totally unaware of this kind of thing. Well, if what you're saying is on target, it means that the MMs are supporting this stock!
Many of you here may not be aware of this, but at the close of Market today Friday 10/9/20, it appears that ENZC CLOSED UP +0.0043 by +27.39% to $0.02 on a Volume of 128 Million.
Below is a cut & paste directly from my Trade Account today after hours.
ENZC ENZOLYTICS
Symbol
ENZC
Last Price x Size
$ 0.02
+0.0043 (+27.39%)
Volume
128M
Can anyone confirm this? It must be correct because it's on my Trade Account and the graft to the right of this data shows an up-swing line to that exact pps at the close of Market.
Great post, thanks!
Great post! Thanks!
Great article! Thanks
Well, one thing's for sure, IF they can by pass animal trials altogether, like the one proposed for Primates at The University of California, Davis or other such places, they would be able to fast track the commercialization of their vaccine all over the world by partnering with a BigPharma player, and that partnership would be a Licensing Arrangement royalties falling to their earnings! If this happens, it will be a major push to get the merged Company into revenue flow that will undoubtedly be reflected in the PPS pushing it UP! My guess would be the dollar range.
It is hope that this is the direction they take because it will definitely save a lot of time, likely a year or more.
Not at all worried about the day-to-day fluctuations in the PPS!
I view these dips as a MAJOR opportunity to accumulate Shares. I consider any PPS in the "Copper" range to be an amazing opportunity that soon will be a far gone thought of the past, one that many will wish they had of taken advantage of.
As a conservative estimate, I discern that when the official announcement of the Merger breaks, the PPS will easily jump north of $ 0.10 which will attract hoards of new investors that will then push the PPS even higher, possibly double or triple that price point within a short time frame, i.e. 0.30+...and when it does, I will just be adding more shares!
Invest...Relax...Be Happy...you couldn't be in a better place at a better time.
As for me, I'm looking to soon ADD an additional 0.5 MILLION shares to bring my holding up to an even MILLION! After that, sky's the limit!
I'll say it again as a BigPharma clinical research professional of over 30 years who holds an M.D. degree and was formally trained as an NIH Principal Investigator, the "Penny trading range of this stock is a once in a lifetime opportunity, that is IF you're in it for the long haul and are also motivated to contribute to the humanitarian-life saving efforts and dedication of the research team of these two Companies who have poured their lives into where they are today.
This to me is a BIG motivating factor to invest in this company stock because I fully comprehend what all this means from seeing hundreds of patients over the years who have terribly suffered due the HIV Virus or have died from it. The fact is, despite the current pharmaceuticals in the market for "treating" HIV, most still die from it in the wake of lengthy suffering.
I strongly believe that all this will change for the better in the near future via the continued dedicated efforts of the researchers behind the scenes at Enzolytics-BioClonetics.
Best wishes to all and have a peaceful weekend!
Decided to take the plunge today and add substantially to add my small initial position of less than 1,200 shares!
As of today, I'm now Holding 0.5 MILLION Shares and will likely increase it to 1-Million next week!
I typically give a lot of analytical thought in anything I do which is consistent with my Clinical Research background in BigPharma, and although I'm hesitant to put money in the OTC, I view the incredible accomplishments this Company has made in the early stages of science based candidate drug discovery, combined with the exclusive patents they have on Clone-3/ITV-1, as a a once in a lifetime opportunity.
My general rationale is that MANY BioPharma leaders started in the exact same place as Enzolytics-BioClonetics.
So ultimately the way I see it, investing in this Company in my mind is simply the right thing to do just based on my desire to be part of a life changing pharmaceutical that can dramatically contribute to the effective treatment of AIDS/HIV and several other related viral infectious diseases.
By they way, many of you are waiting for "news" to break on this company, did you know it ALREADY HAS... 2-Days ago on 10/6/20.
https://microcapdaily.com/the-rise-of-enzolytics-inc-otcmkts-enzc-bioclonetics-merger/128103/
Looks like this Company is officially on everyone's radar and that will only increase with news of the Merger, etc.
Best wishes to all!
Great post! I totally agree with the excellent perspective you provided.
Yes, I definitely discern this Company merged is way under-valued especially when one considers the exclusive Patent they own on their combined technologies and the multiple infectious disease viral vaccine applications associated with it.
Well established BigPharma players could cut a deal with Enz-BioClonetics to mass produce their drug for immediate commercial use in the near future, like you said, by licensing their Patent which by itself is worth Mega-Millions in immediate royalty revenues that will show up in the Quarterly Earnings Reports reflected in its Market Cap.
This would be a game changer and it's definitely the "fast-track" approach that could transform their company literally over night post-merge into a major player in BigPharma! Many doors will open for them as a result.
I believe the Merger itself has the potential to kick-up the PPS into the DOLLAR trading range but still on the OTC.
If fast track commercialization begins via BigPharma partners, the PPS will rapidly rise with transition to one of the major exchanges and its Market Cap will explode!
How long that will take is anyone's guess.
Let's hope that happens! I was just speaking from a qualified professional perspective on how pharmaceuticals are brought to market in the U.S. and the time frame generally involved. I know, because this is my profession as a Clinical Investigator who has extensive experience in drug development over three decades.
Great question!
Here's the short answer:
Phase I - Several months
Phase II- Several months to 2-Years
Phase III - 1 to 4 years
Phase IV - Same as Phase III possibly longer.
Here's a helpful link to review:
https://www.clinicaltrialsandme.com/resources/how-long-do-clinical-trials-take.html
Please keep in mind these are only estimates AND that Enzolytics-BioClonetics will have to conduct ALL 4 Clinical Trial Phases to bring their drug to commercialization.
However the Market always reflects these developments in the Share Price!
For example, if you take a look at today's "Most Read" Stocks here on iHub, in the #1 position at the top is NorthWest Biotherapeutics (NWBO) presently trading at: $ 0.785.
If you go to this Company's website you will see that they are still in the drug development-clinical trial stages with no products on the market.
Here's a excerpt on the front page of their website and the Link to their Company:
"Northwest Biotherapeutics, Inc is a clinical stage biotechnology company focused on the development of cancer vaccines for treating a broad range of solid tumor cancers."
They presently have 4 candidate drugs in development and all 4 of them are in different stages of clinical trials that can be viewed on a chart posted on their website.
https://nwbio.com/
They are engaged in the FDA required Phase I-Phase IV clinical trial process and have four (4) candidate drugs they seek to bring to market listed on their website. As of today they have no drugs on the market, but soon they likely will.
Apparently they just completed Phase III of one of their candidate drugs that's transitioning to Phase IV; another is just entering Phase II; one is soon to enter Phase III; and one is entering Phase I.
https://nwbio.com/clinical-trials/
I hope this explanation helps as it is the same process that Endolytics-BioClonetics will be required to go through for FDA approval.
We're looking at several years before Endolytics-BioClonetics get their HIV/Anti-Viral drug to market.
Once Enzoltics-BioClonetics completes the U.C. Davis Primate Study, if that proves successful, they will quickly advance to Human Subject clinical trial Phase I and onward.
***General Note to ALL*** Everyone here needs to keep in mind that for the above reasons this is a long-term investment play.
EXCELLENT POST! 100% CORRECT on ALL points!
I don't say this lightly having a professional background as a Clinical Investigator from the Big Pharma industry!
For decades I've been directly involved in many Phase III/Phase IV trials that brought several pharmaceuticals to commercialization.
As a result, I have a comprehensive understanding of all the processes involved and I can tell everyone here that the merger of these two (2) BioTech Companies by far have ALL the necessary ingredients to revolutionize treatment of AIDS/HIV owing to their combined scientific discoveries of Clone 3 Recombinant DNA Antibodies and ITV-1 Peptide that together have implications of broad range viral infectious disease treatment applications.
It's absolutely mind blowing what these two Companies have under their belt and IMO there couldn't be a more perfect match for a BioTech merger!
Post-Merger, it's going to be very interesting what the forthcoming Primate studies to be conducted at The University of California Davis will show for combining Enzolytics ITV-1 Peptide in combination with BioClonetics Clone-3 Antibodies on multiple HIV isolates. If these preliminary studies prove to be successful, it would subsequently lead to Phase I-IV Human Subject clinical trials to pursue FDA new drug application.
The combination of official announcement of the 1). merger 2). funding in place; 3). and commencement of The UC Davis Primate Study, will no doubt establish them as a BigPharma "candidate drug developer", with instant global recognition in the medical-scientific community for Novel AIDS/HIV drug treatment development and related viral applications.
Any of these three announcements is going to undoubtedly send the stock price soaring to new heights far beyond where it is now and eventually transition to one of the major Stock Exchanges.
Best of success to all!
Thank you
Great post! Thanks for all the DD and Intel.
New to this Community and recently took a position in ABCE.
What does it mean to "be in Copper?"
Thanks
Please describe WHY that PR and/or CHNC is a SCAM?? Are you saying CHNC can't diversify its business interests?? And what does the DATE of this PR have to do with anything?? Does it need to have a specific date within a certain time frame to be legit??? That PR is less then 12 months ago, so what??
I'm new to this community, what is "Copper Land??"
Thanks
Would anyone like to explain why ENZC closed UP today 10/6/20 just shy of 0.02, but yet nearly 14 MILLION more shares were sold than bought?
Bought
164,279,944
Sold
178,223,277
Difference
13,943,333
http://ih.advfn.com/stock-market/USOTC/enzolytics-pk-ENZC/trades
Am I missing something here?
Thanks
Would anyone like to explain why ENZC closed UP today 10/6/20 just shy of 0.02, but yet nearly 14 MILLION more people sold their shares than bought shares?
Bought
164,279,944
Sold
178,223,277
Difference
13,943,333
http://ih.advfn.com/stock-market/USOTC/enzolytics-pk-ENZC/trades
Am I missing something here?
Thanks
ABCE Energy Inc (ABCE)
0.0011 +0.0002 (+22.22%) 10/06/20 [OTC US]
POST-MARKET 0.0011 unch (unch) 16:00 ET
QUOTE OVERVIEW for Tue, Oct 6th, 2020Alerts Watch Help
Day Low
0.0008
Day High
0.0012
Open 0.0009
Previous Closed 0.0009
Volume 637,864,375
Avg Volume 287,930,719
5-Day Change +0.0007 (+175.00%)
52-Week Range 0.0001-0.0089
ABCE traded today 10/6/20 more than TWICE its Average Volume and > 175% increase in it's pps over the past 5 days!
Nearly 3/4 BILLION trading interest in this stock today, and the Buyers EXCEEDED Sellers by 140 Million, which by itself is WAY higher volume than many stocks trade at.
IMO this is a strong sign that this stock is aggressively moving to new highs due to the FACT that BUYERS are consistently MORE than SELLERS!!!
Not bad!
Abco Energy Inc (ABCE)
0.0011 +0.0002 (+22.22%) 10/06/20 [OTC US]
POST-MARKET 0.0011 unch (unch) 16:00 ET
QUOTE OVERVIEW for Tue, Oct 6th, 2020Alerts Watch Help
Day Low
0.0008
Day High
0.0012
Open 0.0009
Previous Closed 0.0009
Volume 637,864,375
Avg Volume 287,930,719
5-Day Change +0.0007 (+175.00%)
52-Week Range 0.0001-0.0089
ABCE traded today 10/6/20 more than TWICE its Average Volume and > 175% increase in it's pps over the past 5 days!
Nearly 3/4 BILLION trading interest in this stock today, and the Buyers EXCEEDED Sellers by 140 Million, which by itself is WAY higher volume than many stocks trade at.
IMO this is a strong sign that this stock is aggressively moving to new highs due to the FACT that BUYERS are consistently MORE than SELLERS!!!
Not bad!
Yes! It's EXTREMELY rare to see this kind of rating for ANY Penny Stock!...and it's by more than one stock checker platform!
Wallet Investor Rating-Strong Buy
https://walletinvestor.com/stock-forecast/enzc-stock-prediction
Current Price 10/6/20
?0.010 USD
1-Year Forecast *
?11.720 USD
5-Year Forecast *
?26.254 USD
Historical index on US Stock Market : D- "Should I invest in Enzolytics stock?" "Should I trade "ENZC" stock today?" According to our live Forecast System, Enzolytics, Inc. stock is an awesome long-term (1-year) investment*.
At Walletinvestor we predict future values with technical analysis for wide selection of stocks like Enzolytics, Inc. (ENZC).
If you are looking for stocks with good return, Enzolytics, Inc. can be a profitable investment option.
Take away?
12 Month Strike Price Estimate: $26.25
6 Month Strike Price Estimate: $13.12
3 Month Strike Price Estimate: $6.56
Average weekly PPS increase over the next 6 months: $ 0.55/week
Wallet Investor rarely gives an "Awesome" or "Strong Buy" on ANY Stock unless it's trading on the major exchanges with serious earnings!
Plug in any "TOP Penny Stock" listed on Bartchart into the stock search box on Wallet Investor and see what happens. NONE get this kind of rating, in fact they ALL get a "poor" or "don't buy" rating.
However please keep in mind these are only estimates, although IMO I believe these are conservative, AND it's a reasonable assumption based on everything this company has going for it, with its "Clone 3" Patent - Disruptive Technology" for effectively treating most strains of HIV, which may include curative treatment.
Once the merger is announced, SEC filings updated, funding is announced, and Phase IV Trials start, ENZC will be in a totally different universe with the major BigPharmas and the stock price will dramatically rise likely in the double dollar digits!
Keep the faith!
Wallet Investor Rating-Strong Buy
Current Price 10/6/20
?0.010 USD
1-Year Forecast *
?11.720 USD
5-Year Forecast *
?26.254 USD
Historical index on US Stock Market : D- "Should I invest in Enzolytics stock?" "Should I trade "ENZC" stock today?" According to our live Forecast System, Enzolytics, Inc. stock is an awesome long-term (1-year) investment*.
At Walletinvestor we predict future values with technical analysis for wide selection of stocks like Enzolytics, Inc. (ENZC).
If you are looking for stocks with good return, Enzolytics, Inc. can be a profitable investment option.
Take away?
12 Month Strike Price Estimate: $26.25
6 Month Strike Price Estimate: $13.12
3 Month Strike Price Estimate: $6.56
Average weekly PPS increase over the next 6 months: $ 0.55/week
Wallet Investor rarely gives an "Awesome" or "Strong Buy" on ANY Stock unless it's trading on the major exchanges with serious earnings!
Plug in any "TOP Penny Stock" listed on Bartchart into the stock search box on Wallet Investor and see what happens. NONE get this kind of rating, in fact they ALL get a "poor" or "don't buy" rating.
However please keep in mind these are only estimates, although IMO I believe these are conservative, AND it's a reasonable assumption based on everything this company has going for it, with its "Clone 3" Patent - Disruptive Technology" for effectively treating most strains of HIV, which may include curative treatment.
Once the merger is announced, SEC filings updated, funding is announced, and Phase IV Trials start, ENZC will be in a totally different universe with the major BigPharmas and the stock price will dramatically rise likely in the double dollar digits!
Keep the faith!
Doug- Well said! I was just about to post the same thing! To me, as an experienced investor, the fundamental thing I look for is if a stock is consistently advancing to new levels that are above their established ceiling or 52 week high, just like what happened today on 10/5/20 but for different reasons.
Normally I don't invest in Penny Stocks, but this particular one got my attention due to my background in Big Pharma Clinical Trials, and in light of the fact that a merger might take place soon involving serious players in the Monoclonal Landscape who hold an exclusive Patent on Clone-3 Technology for treatment of AIDS/HIV. If it wasn't for this I would likely not invest in this company unless they were much further alone.
In light of this, I opened a limited position today, however in order for me to add to my position, at minimum I'm going to need to see consistent upward PPS movement far North of where it closed today, AND with news of the merger completion.
Only when that happens will I be able to justify increasing my position, but so far this nevertheless remains a speculative play where one can lose all their money in the blink of an eye.
What many amateur investors do is load up on stocks like this going on credit, etc, and throwing all their cash at it not knowing if the bottom is going to fall out at any minute and them being unable to unload their position when they hit the sell button! It can and does happen on speculative plays like this based on its present status on the Pink Sheets! Plainly put, there's no "bottom" in these class of stocks.
This play is "promising" but don't make the mistake of thinking it's not speculative and can blind side you in an instant! Also, if for any reason trading is stopped for any SEC Violations or deficiencies, there's the possibility of everyone losing all their money. I have seen this happen on more than one occasion and everyone went BUST overnight!
Also , I'm not one to engage in "averaging down" especially when a company has no earnings and has not proven itself worthy of serious capital investment. If a company stock is a "volume play only" like this one presently is, my advice is watch out! And "averaging up" only makes sense in general if a company has stable trading history and earnings.
This company is going to need merger completion, updated SEC filings, and news of forthcoming funding for me to seriously invest in it, and I would feel even more comfortable when they announce forth coming funding and planned initiation of their Phase IV Trials.
Until then my perspective is "use extreme caution" but plan to make your move at the right time.
I perceive that Shorts that are sitting on up to 68% of the OS, if they come out in full force tomorrow 10/6/20 are going to push the pps back down close to the range of .007 to .009 and this will be amplified by individuals locking in profits at market dumping millions of shares.
This is only an opinion and it may or may not happen.
Either way, I'm in a holding pattern until things improve for this company and I also plan on using my connections in Big Pharma to get in touch with the principals of this company to learn more about the design of their Phase IV trial, forthcoming funding sources, and when this might take place.
Best of success to everyone!
Happy trading!